524280 Stock Overview
An integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Kopran Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹199.65 |
52 Week High | ₹369.20 |
52 Week Low | ₹198.05 |
Beta | 0.58 |
11 Month Change | -29.87% |
3 Month Change | -35.52% |
1 Year Change | -24.40% |
33 Year Change | -22.69% |
5 Year Change | 484.63% |
Change since IPO | 144.82% |
Recent News & Updates
Recent updates
Shareholder Returns
524280 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -11.6% | -0.2% | 0.3% |
1Y | -24.4% | 40.5% | 27.3% |
Return vs Industry: 524280 underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: 524280 underperformed the Indian Market which returned 27.3% over the past year.
Price Volatility
524280 volatility | |
---|---|
524280 Average Weekly Movement | 8.8% |
Pharmaceuticals Industry Average Movement | 6.0% |
Market Average Movement | 6.1% |
10% most volatile stocks in IN Market | 9.2% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 524280's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 524280's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1958 | 842 | Surendra Somani | www.kopran.com |
Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular.
Kopran Limited Fundamentals Summary
524280 fundamental statistics | |
---|---|
Market cap | ₹9.63b |
Earnings (TTM) | ₹528.93m |
Revenue (TTM) | ₹6.36b |
18.2x
P/E Ratio1.5x
P/S RatioIs 524280 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
524280 income statement (TTM) | |
---|---|
Revenue | ₹6.36b |
Cost of Revenue | ₹4.15b |
Gross Profit | ₹2.21b |
Other Expenses | ₹1.69b |
Earnings | ₹528.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 10.97 |
Gross Margin | 34.83% |
Net Profit Margin | 8.32% |
Debt/Equity Ratio | 25.0% |
How did 524280 perform over the long term?
See historical performance and comparison